BioTime has signed an exclusive sublicense agreement and a supply agreement with Jade Therapeutics for ophthalmological drug delivery applications of HyStem technology. According to the agreement, BioTime will provide Jade with ...
Tags: HyStem technology, Biotime, Jade Therapeutics, ophthalmological drug